Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition
pubmed.ncbi.nlm.nih.gov shows its articles on its own site.
Read the article on pubmed.ncbi.nlm.nih.gov ↗Article · Jan 2023 · 1 min read
In brief
In brief
This study identifies two molecularly distinct Ewing sarcoma subsets based on IGF1R localization and replication stress levels, with differing responses to IGF1R and WEE1 inhibitors. Combined inhibition showed efficacy across both tumor types, suggesting a biomarker-driven approach for treatment selection in relapsed/metastatic disease.
Written by the GCMD Library team from the article.
Statements in this article
Ewing sarcoma tumors fall into two molecularly defined groups based on IGF1R localization, replication stress levels, and drug sensitivity patterns.
Tumors with predominantly nuclear IGF1R have upregulated DNA damage tolerance pathways, low replication stress, low RRM2B levels, and high levels of WEE1 and RAD21.
Tumors with nuclear IGF1R are relatively insensitive to IGF1R inhibition.
Tumors with membrane-associated IGF1R have high replication stress, high RRM2B levels, low levels of WEE1 and RAD21, and are sensitive to IGF1R or WEE1-targeted inhibitors.
Matched primary and metastatic tumors from the same patient differ in IGF1R localization, levels of replication stress, and inhibitor sensitivity.
Combined IGF1R and WEE1 inhibition shows activity across both tumor subsets.